Kintor Pharma Announces Publication of Phase Ib Data from Pruxelutamide for AR+ mBC in EJC
- Thursday, September 29, 2022, 1:26
- Finance
- Add a comment
SUZHOU, China, Sept. 29, 2022 /PRNewswire/ — Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the results from a phase Ib study of pruxelutamide…
About the Author
adminasapcorp has written 39319 stories on this site.